tuberculosis and malarialatest news & developments
To end Aids by 2043, the South African government says it could get a group of local pharmaceutical companies to make generic shots of lenacapavir from 2027 onwards. There is, however, a hitch. None of the companies that will be involved have a licence to make the jab. (Julia Koblitz/ Unsplash)

SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab

  • Eyaaz
9 min read
Newborn children in sub-Saharan Africa are 14 times more likely to die within the first month than those in high-income regions such as Australia and New Zealand.

Close the global healthcare gap: Solutions for a more equitable future

A comprehensive, multi-sector approach would help medical care in emerging countries catch up with those in more established nations

5 min read